The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate ...

Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major ...

CMS announces billions in savings for Medicare when first and second rounds of negotiations go into effect in 2026 and 2027, ...

Medicare’s 2026 drug price negotiations under the Inflation Reduction Act aim to lower the cost of expensive medications, ...

Bayer's successful trial comes after it previously halted a phase 3 clinical trial testing the effectiveness of the same experimental drug for stroke and systemic embolism prevention in 2023. At the ...

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

Bayer AG said an experimental stroke-prevention drug showed positive results in a late-stage study, a boost for the German ...

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and ...

Bayer reported a major boost to its drug pipeline on Monday morning, after its experimental anticoagulant asundexian delivered positive results in a large phase three trial, easing concerns following ...

The hospital lobby has filed a lawsuit seeking to block the federal government’s 340B Rebate Model Pilot Program, which is ...

Medicare Part B costs will rise in 2026. Here's what to expect, including higher prescription drug prices and payment changes that will affect your wallet.